tetrofosmin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
insecticides, anthelminthics, pesticides etc., phosphorous derivatives 3592 127502-06-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tetrofosmin
Tetrofosmin is a diagnostic agent used to assess areas of reversible myocardial ischemia in the presence or absence of infracted myocardium and is also used to assess ventricular function.
  • Molecular weight: 382.46
  • Formula: C18H40O4P2
  • CLOGP: -0.69
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 36.92
  • ALOGS: -5.76
  • ROTB: 19
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP2K6,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK2,PDK4,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1 33
kinase-selectivity-class AXL,BRAF,CAMK2A,CAMK2D,CDK4,CDK9,CHUK,EPHB4,GRK2,INSR,MAP2K6,MAPK7,MTOR,PIK3CD,PTK2,SIK2,STK33,TEK 18
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
No adverse event 450.10 75.32 88 217 67894 90560248
Radioisotope scan abnormal 361.33 75.32 38 267 291 90627851

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Radioisotope scan abnormal 456.60 80.98 50 248 261 42620776
No adverse event 453.45 80.98 91 207 38930 42582107

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
No adverse event 342.59 58.69 72 306 73767 110515154
Radioisotope scan abnormal 310.20 58.69 36 342 701 110588220
Drug ineffective 59.54 58.69 45 333 1520495 109068426

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D06094 KEGG_DRUG
C1366036 UMLSCUI
CHEBI:135598 CHEBI
CHEMBL1615784 ChEMBL_ID
DB11180 DRUGBANK_ID
4274 PUBCHEM_CID
6886 INN_ID
3J0KPB596Q UNII
1311569 RXNORM
23732 MMSL
d06761 MMSL
009786 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Myoview HUMAN PRESCRIPTION DRUG LABEL 1 17156-024 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.23 mg INTRAVENOUS NDA 26 sections
Myoview HUMAN PRESCRIPTION DRUG LABEL 1 17156-026 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1.38 mg INTRAVENOUS NDA 24 sections
Tetrofosmin HUMAN PRESCRIPTION DRUG LABEL 1 51808-223 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.35 mg INTRAVENOUS Unapproved drug other 7 sections
Tetrofosmin HUMAN PRESCRIPTION DRUG LABEL 1 51808-223 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.35 mg INTRAVENOUS Unapproved drug other 7 sections